On December 27, 2018, the Issuer entered into a certain Term Loan Credit and Security Agreement, dated as of December 27, 2018 (as the same may be amended, modified, supplemented, renewed, restated or replaced from time to time, the "Term Loan Credit Agreement"), with Quantum LTO Holdings, LLC, a wholly-owned subsidiary of the Issuer ("Quantum LTO"), certain Blue Torch Funds, other borrowers and guarantors from time to time party thereto, the lenders from time to time party thereto (collectively, the "Term Loan Parties"), and U.S. Bank National Association, as disbursing agent and collateral agent for such Term Loan Parties. In connection with the December Term Loan Credit Agreement, on December 27, 2018, the Issuer issued to certain Blue Torch Funds warrants (the "December 2018 Term Loan Warrants") to purchase an aggregate of 2,859,608 shares of the Common Stock at an exercise price of $1.33 per share. The Warrants are exercisable until December 27, 2028. Upon exercise, the aggregate exercise price may be paid, at each warrant holder's election, in cash or on a net issuance basis, based upon the fair market value of the Common Stock at the time of exercise. On June 16, 2020, the Issuer entered into an amendment (the "June Term Loan Amendment") to the Term Loan Credit Agreement with the Term Loan Parties and U.S. Bank National Association, as disbursing agent and collateral agent for such Term Loan Parties. In connection with the June Term Loan Amendment, on June 16, 2020, the Issuer issued to certain Blue Torch Funds warrants (the "June 2020 Term Loan Warrants") to purchase an aggregate of 1,484,007 shares of the Common Stock, at a purchase price of $3.00 per share. On May 24, 2024, the Issuer entered into an amendment and waiver (the "May Term Loan Amendment") to the Term Loan Credit and Security Agreement with the Term Loan Parties and Blue Torch Finance LLC, as disbursing agent and collateral agent for such Term Loan Parties. In connection with the May Term Loan Amendment, on May 24, 2024, the Issuer issued to certain Blue Torch Funds warrants (the "May 2024 Term Loan Warrants") to purchase an aggregate of 1,251,196 shares of the Common Stock, at a purchase price of $0.46 per share. On July 11, 2024, the Issuer entered into an amendment (the "July Term Loan Amendment") to the Term Loan Credit Agreement with the Term Loan Parties and Blue Torch Finance LLC, as disbursing agent and collateral agent for such Term Loan Parties. In connection with the July Term Loan Amendment, on July 11, 2024, the Issuer issued to certain Blue Torch Funds warrants (the "July 2024 Term Loan Warrants") to purchase an aggregate of 625,000 shares of Common Stock, at an agreed purchase price. On August 13, 2024, the Issuer entered into an amendment (the "August Term Loan Amendment") to the Term Loan Credit Agreement with the Term Loan Parties. In connection with the August Term Loan Amendment, on August 13, 2024, the Issuer issued to certain Blue Torch Funds warrants to purchase an aggregate of 3,125,000 shares of Common Stock, at an exercise price of $0.31 per share, the closing price of the Common Stock on the date immediately preceding the signing of the warrant agreement (the "August 2024 Term Loan Warrants" and together with the December 2018 Term Loan Warrants, June 2020 Term Loan Warrants, May 2024 Term Loan Warrants and the July 2024 Term Loan Warrants, the "Warrants"). In addition, pursuant to the August Term Loan Amendment, the Issuer agreed to lower the exercise price of the December 2018 Term Loan Warrants, June 2020 Term Loan Warrants, May 2024 Term Loan Warrants and the July 2024 Term Loan Warrants held by the Blue Torch Funds to $0.31 per share. Upon exercise, the aggregate exercise price may be paid, at each Warrant holder's election, in cash or on a net issuance basis, based upon the fair market value of the Common Stock at the time of exercise. Each Blue Torch Fund's ability to convert the Warrants was subject to a blocker provision (the "Blocker") that would prohibit any Blue Torch Fund from beneficially owning more than 4.99% of the outstanding Common Stock at any time, determined in accordance with rules promulgated under the Securities Exchange Act of 1934, as amended. Pursuant to the terms of the Warrants, the Blocker could not be changed without written consent of the Issuer. On August 26, 2024, the Issuer effected a 1-for-20 reverse stock split (the "Reverse Stock Split") in which every 20 issued shares of Common Stock was automatically reclassified into one issued share of Common Stock. No fractional shares were issued as a result of the Reverse Stock Split. Consequently, the Reporting Persons beneficially owned a total of 467,248 shares of Common Stock issuable upon exercise of Warrants, subject to the Blocker. Pursuant to the Reverse Stock Split, the exercise price of the Warrants was increased to $6.20 per share. On December 27, 2024, the Blue Torch Funds and the Issuer agreed to increase the Blocker to 9.99%. As a result, the Reporting Persons beneficially owned 467,248 shares of Common Stock issuable upon exercise of Warrants, representing 8.8% of the shares of Common Stock outstanding at such time, assuming the exercise of the Warrants. Subsequently, on December 27, 2024, the Blue Torch Funds exercised the Warrants in a cashless exercise and were issued an aggregate of 405,978 shares of Common Stock, representing 7.7% of the shares of Common Stock outstanding at such time. As a result, the Reporting Persons no longer beneficially own any Warrants of the Issuer. Pursuant to the terms of the Warrants held by the Blue Torch Funds, the Issuer granted certain Blue Torch Funds, the right, for as long as they or their affiliates hold any Common Stock issuable upon exercise of warrants, to have one observer attend and participate in meetings of the board of directors (the "Board") in a non-voting capacity. Although the Reporting Persons do not currently have any specific plans or proposals with respect to the Issuer, the Reporting Persons may communicate with the Issuer's management and Board about the Issuer's operations, management, Board composition, capital structure and/or corporate structure, dividend and/or buyback policies, and strategy, in addition to past and/or potential transactions involving the Issuer and/or certain of the Issuer's businesses or assets, and may communicate with other shareholders and/or third parties regarding the Issuer and the foregoing. The Reporting Persons may explore, develop and/or make plans and/or proposals (whether preliminary or final) with respect to the foregoing, including prior to forming an intention to engage in such plans and/or make such proposals. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and depending upon various factors, including, without limitation, the Issuer's financial position and strategic direction, the outcome of any discussions or matters referenced above, overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor (i) to increase or decrease their position in the Issuer through, among other things, the purchase or sale of securities of the Issuer, including through transactions involving the Common Stock and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer in the open market or in private transactions, including through a trading plan created under Rule 10b5-1(c) or otherwise, on such terms and at such times as the Reporting Persons may deem advisable and/or (ii) to enter into transactions that increase or hedge their economic exposure to the Common Stock without affecting their beneficial ownership of the Common Stock. In addition, the Reporting Persons may, at any time and from time to time, (i) review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto and (ii) consider or propose one or more of the actions described in subparagraphs (a) - (j) of Item 4 of Schedule 13D.